复星医药(02196.HK)：药友制药授予辉瑞“GLP-1R”激动剂全球独家许可 首付款1.5亿美元

Core Viewpoint - Fosun Pharma (02196.HK) announced that its subsidiary, YaoYao Pharmaceutical, has granted Pfizer exclusive rights for the development, use, production, and commercialization of oral small molecule GLP-1 receptor agonists, including YP05002, across a global licensing area and for all human and animal indications [1] Group 1 - YaoYao Pharmaceutical will receive a non-refundable upfront payment of $150 million as part of the licensing agreement [1] - The agreement includes potential milestone payments of up to $350 million based on the clinical and commercialization progress of the licensed products [1]